Get the Stockscreener App
1.58
1.28%
0.02
After Hours:
1.55
-0.03
-1.90%
Repare Therapeutics Inc stock is traded at $1.58, with a volume of 221.56K.
It is up +1.28% in the last 24 hours and up +13.67% over the past month.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
See More
Previous Close:
$1.56
Open:
$1.57
24h Volume:
221.56K
Relative Volume:
0.69
Market Cap:
$67.77M
Revenue:
$51.13M
Net Income/Loss:
$-93.80M
P/E Ratio:
-0.7085
EPS:
-2.23
Net Cash Flow:
$-129.10M
1W Performance:
+5.33%
1M Performance:
+13.67%
6M Performance:
+37.39%
1Y Performance:
-59.90%
1-Day Range:
$1.56
$1.62
1-Week Range:
$1.5005
$1.62
52-Week Range:
$0.89
$4.22
Repare Therapeutics Inc Stock (RPTX) Company Profile
Name
Repare Therapeutics Inc
Sector
Industry
Phone
(857) 412-7018
Address
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Compare RPTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
1.58 | 66.91M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-23 | Upgrade | Stifel | Hold → Buy |
| Feb-03-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-06-23 | Initiated | CapitalOne | Overweight |
| Apr-12-22 | Downgrade | Stifel | Buy → Hold |
| Mar-17-22 | Resumed | Goldman | Buy |
| Sep-23-21 | Initiated | Stifel | Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Buy |
| Jun-28-21 | Initiated | Guggenheim | Buy |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Oct-28-20 | Initiated | Northland Capital | Outperform |
| Jul-14-20 | Initiated | Cowen | Outperform |
| Jul-14-20 | Initiated | Goldman | Neutral |
| Jul-14-20 | Initiated | Morgan Stanley | Overweight |
| Jul-14-20 | Initiated | Piper Sandler | Overweight |
View All
Repare Therapeutics Inc Stock (RPTX) Latest News
How many analysts rate Repare Therapeutics Inc. as a “Buy”Market-beating returns - jammulinksnews.com
Pattern recognition hints at Repare Therapeutics Inc. upsideFree News Based Entry Opportunity Alerts - Newser
Will Repare Therapeutics Inc. benefit from macro trendsTrade Safety Report with Pattern Insights - Newser
Best data tools to analyze Repare Therapeutics Inc. stockValue Investing Summary and Earnings Outlook - Newser
Quantitative breakdown of Repare Therapeutics Inc. recent moveLong-Term Investment Strategy Impact Analysis - Newser
Can Repare Therapeutics Inc. hit a new high this monthEquity Forecast with Predictive AI Screener - Newser
How high can Repare Therapeutics Inc. stock go Strong Buy Signal Summary with Entry Zone - Newser
Repare Therapeutics (NASDAQ:RPTX) Trading 0.6% HigherHere's What Happened - MarketBeat
What are the technical indicators suggesting about Repare Therapeutics Inc.Consistently high yield - jammulinksnews.com
What are Repare Therapeutics Inc. company’s key revenue driversInvest smarter with comprehensive market analysis - jammulinksnews.com
How strong is Repare Therapeutics Inc. company’s balance sheetDiscover dynamic stocks ready to soar - jammulinksnews.com
Is Repare Therapeutics Inc. Stock a Good Fit for Conservative InvestorsFree Exclusive Group - Newser
ARK Investment Management LLC Sells 875,514 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - MarketBeat
How Repare Therapeutics Inc. stock performs during market volatilityLow Risk Trading Ideas - Newser
Repare Therapeutics (NASDAQ:RPTX) Trading 0.6% Higher – What’s Next? - Defense World
Is Repare Therapeutics Inc. a good long term investmentMassive portfolio appreciation - PrintWeekIndia
Will Repare Therapeutics Inc. stock benefit from interest rate changesExplosive earnings growth - jammulinksnews.com
Why Repare Therapeutics Inc. stock is on top investor watchlistsUnrivaled growth potential - jammulinksnews.com
What analysts say about Repare Therapeutics Inc. stock outlookMarket-leading growth rates - jammulinksnews.com
What drives Repare Therapeutics Inc. stock priceFree Wealth Planning Blueprint - Autocar Professional
What analysts say about Repare Therapeutics Inc. stockPowerful growth strategies - jammulinksnews.com
Why Repare Therapeutics Inc. stock attracts strong analyst attentionFree Access to Community - Newser
Repare Therapeutics Inc. Stock Analysis and ForecastUnprecedented growth rates - jammulinksnews.com
what makes repare therapeutics inc. stock price move sharplyLow Risk Profit Ideas - Newser
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
Repare Therapeutics Jumps 15% After $10M Licensing Deal With Debiopharm - Yahoo Finance
Repare Therapeutics Inc Stock (RPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Repare Therapeutics Inc Stock (RPTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER |
Mar 12 '25 |
Sale |
1.14 |
5,611 |
6,397 |
80,297 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Mar 12 '25 |
Sale |
1.14 |
6,884 |
7,848 |
54,786 |
| Segal Lloyd Mitchell | PRESIDENT AND CEO |
Mar 12 '25 |
Sale |
1.14 |
21,179 |
24,144 |
124,394 |
1.32%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):